WebThe p53 protein, a tumor suppressor, is inactivated in many human cancers through mutations or by its interaction with an oncoprotein, MDM2. Blocking the MDM2–p53 protein-protein interaction has the effect of activating wild-type p53 and has been pursued as a novel anticancer strategy. Web21 de dic. de 2024 · MDM2 is a key oncogenic protein that serves as a negative regulator of the tumor suppressor p53. While a number of inhibitors of the MDM2-p53 interaction …
Resistance mechanisms to inhibitors of p53-MDM2 interactions …
Web15 de abr. de 2003 · Molecular characterization of the p53 protein has shown that its conformational flexibility and intrinsic thermodynamic instability provide a foundation from … Web12 de abr. de 2024 · MDM2 is a protein that is important in regulation of the expression of the p53 protein. If this protein is ... A.M. Somboro, R.B. Khan, H.M. Kumalo, Heat shock protein 90 (HSP90) inhibitors as anticancer medicines: a review on the computer-aided drug discovery approaches over the past five years. Comput. Math. Methods. Med. 31 ... malta mustangs football schedule
靶向作用p53药物的研究进展_参考网
Web15 de dic. de 2024 · In this review, we focus on MDM2 inhibitors that were designed to disrupt MDM2-p53 binding and thus activate wild-type p53, such as nutlin. Many small molecule inhibitors have entered clinical trials, often in combination with other therapeutics. Web近年来,很多小分子化合物、多肽等都被证实以p53为作用靶点而产生抗肿瘤生物活性[6]。本文将着重阐述以p53为靶点的药物研究进展,进而讨论相关化合物在肿瘤治疗中的作用机制。 1 p53基因突变与肿瘤. 分析显示,很多p53突变的癌症病人存活率相对较低[7]。 Web22 de ago. de 2024 · P53 protein phosphorylation induced by cisplatin can reduce the cisplatin resistance, while increased MDM2 expression and non-phosphorylated p53 can be detected in cisplatin-resistant tumor cells. This process may be related to the regulation of loop auxiliary factor p73. malta music charts